Compounds > voltarol
Page last updated: 2024-12-07

voltarol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Voltarol, also known as diclofenac, is a nonsteroidal anti-inflammatory drug (NSAID) commonly used to treat pain and inflammation. It is synthesized from 2,6-dichloroaniline and phenyl acetic acid. Diclofenac works by inhibiting the production of prostaglandins, which are chemicals that cause pain and swelling. Diclofenac is effective in treating a wide range of conditions, including osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and menstrual cramps. It is also used to reduce the risk of cardiovascular events in patients with a history of heart attack. Diclofenac is widely studied due to its effectiveness in treating pain and inflammation, and its potential side effects, such as gastrointestinal bleeding and cardiovascular problems. Researchers are continually exploring new uses and formulations of diclofenac to improve its efficacy and safety.'

diclofenac diethylamine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115087
SCHEMBL ID1116300
MeSH IDM0006285

Synonyms (37)

Synonym
diclofenac diethylammonium salt
diclofenac diethylamine salt
diclofenac diethylammonium
voltarol
78213-16-8
voltaren emulgel (tn)
diclofenac diethylamine
D07817
n-ethylethanaminium{2-[(2,6-dichlorophenyl)amino]phenyl}acetate
unii-6tgq35z71k
6tgq35z71k ,
FT-0603077
diclofenac diethylammonium salt [mi]
diclofenac diethylamine [mart.]
diclofenac diethylamine [who-dd]
AKOS015907253
S3063
HY-15036A
diclofenac (diethylamine)
KS-5039
SCHEMBL1116300
HMS3651L18
mfcd01862249
diclofenac diethylamine (diethylammonium diclofenac)
SW219367-1
diethylamine 2-(2-(2,6-dichlorophenylamino)phenyl)acetate
BCP24521
4-bromo-4-methoxybiphenyl
HMS3885E07
CCG-268279
H10150
Q27265501
A923342
SY110689
[2-(2,6-dichloroanilino)phenyl]acetic acid--n-ethylethanamine (1/1)
DTXSID40999449
2-[2-(2,6-dichloroanilino)phenyl]acetic acid;n-ethylethanamine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"This research aims at formulation of controlled release dosage form containing curcumin microspheres and diclofenac diethylamine and then incorporating it into gel formulation for treatment of inflammation associated with rheumatoid arthritis."( Controlled Release Gel Encompassing Curcumin Microspheres and Diclofenac Diethylamine for Feat Against Arthritis Inflammation.
Dabre, S; Singh, P, 2020)		0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (45.45)24.3611
2020's6 (54.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.40 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index158.73 (26.88)
Search Engine Supply Index3.79 (0.95)

This Compound (54.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (18.18%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
celecoxib
[no description available]		2.1710organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
diclofenac
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.		5.95112amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		2.2510aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
ConditionIndicatedRelationship StrengthStudiesTrials
Osteoarthritis of Knee
[description not available]		04.1521
Osteoarthritis, Knee
Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)		04.1521
Joint Pain
[description not available]		02.3110
Arthritis, Degenerative
[description not available]		02.3110
Ache
[description not available]		04.1521
Osteoarthritis
A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.		02.3110
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		04.1521
Arthralgia
Pain in the joint.		02.3110
Ankle Injuries
Harm or hurt to the ankle or ankle joint usually inflicted by an external source.		03.811
Adjuvant Arthritis
[description not available]		02.2510
Lassitude
[description not available]		02.1510
Fatigue
The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.		02.1510
Back Ache
[description not available]		02.1310
Back Pain
Acute or chronic pain located in the posterior regions of the THORAX; LUMBOSACRAL REGION; or the adjacent regions.		02.1310
Anasarca
[description not available]		02.1710
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.1710